Prevalence of non–cytochrome P450–mediated metabolism in food and drug administration–approved drugs: 2005–2024
Drug Metabolism and Disposition · 2026
DOI: 10.1016/j.dmd.2026.100234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026. Verfasst von Matthew A Cerny. Beteiligte Einrichtung: Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Inc, Groton, Connecticut. Electronic address: matthew.cerny@pfizer.com. Hauptthemen laut MEDLINE: Cytochrome P-450 Enzyme System. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Pfizer.
Abstract (Originalsprache)
Based on literature reports of the increasing importance of non-cytochrome P450 (non-P450) metabolism, an initial evaluation of the prevalence of non-P450 metabolism was undertaken and published in 2016. This initial evaluation covered 10 years and included 125 intravenously and orally administered small-molecule drugs approved by the US Food and Drug Administration. However, the current evaluation has been expanded to cover 20 years (2005-2024) of US Food and Drug Administration-approved drugs and includes 316 small-molecule intravenously and orally administered drugs for which adequate data from human radiolabeled absorption, distribution, metabolism, and excretion are available. Contributions of P450 and non-P450 enzymes to the formation of major metabolites (≥10% of dose) were assessed and tabulated. The involvement of P450 versus non-P450 enzymes in the formation of major metabolites is compared, and the individual non-P450 enzymes responsible are described. This second analysis indicates that non-P450 enzymes contribute significantly to the metabolism of the 316 drugs analyzed with approximately 30% of the metabolism of these drugs carried out by non-P450 enzymes, with the predominant non-P450 enzymes identified being glucuronosyltransferases (10.2%), hydrolases (8.2%), gut microbes (2.7%), and carbonyl reductases (2.6%). As with the previous assessment, the relative contribution of non-P450 enzymes to drug metabolism does not appear to have increased dramatically over the last 20 years of drugs analyzed. Metabolism by uridine 5'-diphospho-glucuronosyltransferase, hydrolase, and carbonyl-reducing enzymes, as well as by gut microbes, is significant and occurs frequently through the 20 years being evaluated. Therefore, further efforts toward characterizing non-P450 metabolism will be needed because it is anticipated that metabolism by non-P450 enzymes will continue to be prevalent in new drug approvals and especially in early drug discovery and development. SIGNIFICANCE STATEMENT: Understanding the metabolic fate of drugs and the enzymes involved in their metabolism is a major focus in both drug discovery and development and provides insights into the possible impact of polymorphic enzymes and drug-drug interaction potential. The current evaluation indicates that although there has not been a temporal increase in non-cytochrome P450 metabolism, metabolism by non-cytochrome P450 enzymes such as uridine 5'-diphospho-glucuronosyltransferase, hydrolases, carbonyl reductase, and gut microbes continues to be prevalent in drug approvals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Inc, Groton, Connecticut. Electronic address: matthew.cerny@pfizer.com.
Förderung
- Pfizer
Zitieren
APA
Cerny, M. A. (2026). Prevalence of non–cytochrome P450–mediated metabolism in food and drug administration–approved drugs: 2005–2024. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2026.100234
Vancouver
Cerny MA. Prevalence of non–cytochrome P450–mediated metabolism in food and drug administration–approved drugs: 2005–2024. Drug Metabolism and Disposition. 2026. doi:10.1016/j.dmd.2026.100234
BibTeX
@article{Cerny2026,
author = {Cerny, Matthew A},
title = {Prevalence of non–cytochrome P450–mediated metabolism in food and drug administration–approved drugs: 2005–2024},
journal = {Drug Metabolism and Disposition},
year = {2026},
doi = {10.1016/j.dmd.2026.100234}
}
EUVIMED